Pharma channel feed

In an­oth­er win for Trump, Mer­ck takes the drug pric­ing pledge. Its cuts are a joke, but is this an in­dus­try tip­ping point?

7 years ago

FDA’s CDER un­veils de­tails of re­or­ga­ni­za­tion

7 years ago

The Shkre­li rule? FDA is ex­plor­ing whether se­lect­ed reim­por­ta­tion could crip­ple the drug prof­i­teers

7 years ago

Go­ing deep­er in­to the ezce­ma game, No­var­tis or­ches­trates $1.1B deal for a Mor­phoSys/Gala­pa­gos drug

7 years ago
R&D

UK votes to stay in the EMA post-Brex­it

7 years ago

J&J joins block­buster HIV com­bo race with new­ly ap­proved 4-in-1 pill

7 years ago

By the num­bers: Se­ries A rounds are bust­ing out, plat­forms are in, M&A is down, val­u­a­tions surge and 2018 looks wicked big

7 years ago
Financing
Deals

No­var­tis CEO Vas Narasimhan hits the brakes on US drug price hikes -- right af­ter tap­ping the gas

7 years ago

An­ti­fun­gal out, can­cer in: Rev­o­lu­tion scores $500M Sanofi deal on first on­col­o­gy pro­gram

7 years ago

An­oth­er stark warn­ing over CRISPR/Cas9’s po­ten­tial to do last­ing harm dents share prices

7 years ago

Phar­ma 'greed' emerges as a po­tent po­lit­i­cal is­sue in a rau­cous elec­tion year

7 years ago

Tak­ing on biode­fense threats, an­tibi­otics mak­er Spero inks $54M in gov­ern­ment deals

7 years ago
R&D

Guard­ing against a night­mare sce­nario, FDA ap­proves new drug to counter small­pox out­break

7 years ago

Af­ter long de­lay fol­low­ing pa­tient death, FDA lifts tri­al hold on Ad­vax­is/As­traZeneca com­bo

7 years ago

Sen­ate Dems blast No­var­tis’ ties to Trump at­tor­ney, claim phar­ma gi­ant of­fered mis­lead­ing ex­pla­na­tions in damn­ing re­port

7 years ago

Am­gen, UCB are back pitch­ing once-re­ject­ed os­teo­poro­sis drug ro­mo to the FDA — but big hur­dles lie ahead

7 years ago

FDA lays down the law on gene ther­a­py, of­fer­ing guid­ances on both dis­eases and pro­ce­dures

7 years ago
Cell/Gene Tx

Ra­maswamy’s Der­ma­vant bags GSK’s PhI­II-ready pso­ri­a­sis drug in $330M deal — eye­ing a ma­jor league con­test

7 years ago
R&D

Gen­mab puts down $54M for im­munother­a­py col­lab­o­ra­tion — ready to spend mil­lions more

7 years ago

VC mon­ey booms in Q2, with mega-deals hit­ting record lev­els

7 years ago

Sen­a­tor Wyden prods Trump/Pfiz­er for de­tails, call­ing drug pric­ing stunt 'long on the­atrics, short on re­lief'

7 years ago

Pfiz­er reshuf­fles, split­ting in­to three busi­ness units

7 years ago

No­var­tis punts a late-stage PI3K drug with a wor­ry­ing safe­ty pro­file to one of Chi­na’s up­start biotechs

7 years ago
R&D

Trump claims a big win over Big Phar­ma, forc­ing Pfiz­er to walk back drug price hikes

7 years ago
First page Previous page 293294295296297298299 Next page Last page
A service from the Financial Times